Azenta Gestione
Criteri Gestione verificati 0/4
Azenta Il CEO è John P. Marotta, nominato in Sep2024, e ha un mandato di 1.67 anni. la retribuzione annua totale è $ 10.37M, composta da 8.7% di stipendio e 91.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.083% delle azioni della società, per un valore di $ 671.90K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.7 anni e 2.3 anni.
Informazioni chiave
John P. Marotta
Amministratore delegato
US$10.4m
Compenso totale
| Percentuale dello stipendio del CEO | 8.68% |
| Mandato del CEO | 1.7yrs |
| Proprietà del CEO | 0.08% |
| Durata media del management | 1.7yrs |
| Durata media del Consiglio di amministrazione | 2.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento della narrazione • May 01
AZTA: 2026 Guidance And Space Research Partnership Will Support Sentiment Recovery
Azenta's updated analyst price target has moved modestly lower by about $0.77, as analysts factor in refreshed assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E following a series of recent target cuts from major firms. Analyst Commentary Recent Street research has focused on recalibrating Azenta's fair value, with several firms trimming their price targets by between $5 and $10 as they reassess assumptions for growth, profitability, and appropriate P/E levels.Aggiornamento della narrazione • Apr 15
AZTA: 2026 Guidance And Space Research Will Support Sentiment Recovery
Azenta's analyst price target has been trimmed by about $2.50 as analysts factor in updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E following a series of recent target cuts from major firms. Analyst Commentary Recent Street research on Azenta points to a more cautious tone on valuation, with multiple price target trims clustering over a relatively short period.Aggiornamento della narrazione • Apr 01
AZTA: 2026 Guidance And Space Research Tests Will Support Sentiment Recovery
Azenta's analyst price targets have been reduced by $5 to $9 in recent updates, as analysts factor in revised expectations for the diagnostic tools group and place greater emphasis on 2026 guidance and the clarity of the company's multi year growth framework. Analyst Commentary Recent research updates on Azenta show a mix of optimism around the long term framework and caution around the nearer term setup, with price targets adjusted both higher and lower as estimates and expectations are refreshed.Seeking Alpha • Mar 24
Azenta: Life Science Player Fails To Come To Life
Summary Azenta, Inc. trades near $20, with operating assets valued at just 0.5x sales and a robust net cash position around $600 million. Recent AZTA developments include the UK Biocentre acquisition and B Medical Systems divestiture, with the latter removing a key earnings drag. Despite a soft Q1 and margin pressure, Azenta maintains full-year guidance, supported by remediation efforts and interest income. The AZTA risk/reward is compelling at current levels, given low expectations, significant liquidity, and underappreciated asset value, making me a buyer despite above-average risks. Read the full article on Seeking AlphaAggiornamento della narrazione • Mar 18
AZTA: 2026 Guidance And Space Research Partnership Will Support Sentiment Recovery
Azenta's analyst price targets have edged lower by a mid single digit dollar amount to around $39, as analysts factor in updated discount rate and growth assumptions, while still highlighting the importance of 2026 guidance and multi year frameworks for potential upside. Analyst Commentary Bullish Takeaways Bullish analysts point to the move to a US$39 price target as a reflection of clearer multi year planning, which supports their view that the company has several paths to grow into that valuation over time.Aggiornamento della narrazione • Mar 03
AZTA: 2026 Framework And Buybacks Will Underpin Sentiment Recovery
Narrative Update: Azenta Azenta's latest analyst price targets have shifted slightly lower in recent research updates, with firms trimming their views by $5 and $9 after a prior increase to $39, as analysts factor in group wide adjustments in diagnostic tools and place more weight on visibility into the company's multi year framework and 2026 guidance. Analyst Commentary Recent research updates on Azenta reflect a mix of optimism about the long term setup and caution around execution and visibility, especially as analysts refresh their views on the broader diagnostic tools group and Azenta's multi year framework.
Nuova narrazione • Feb 25
Automation And Biorepositories Will Steadily Support A Fairly Valued Long Term Outlook
Catalysts About Azenta Azenta provides life sciences customers with sample management, biorepositories and multiomics services such as next-generation sequencing and gene synthesis. What are the underlying business or industry changes driving this perspective?Aggiornamento della narrazione • Feb 17
AZTA: 2026 Margin Framework And Buybacks Will Support Future Upside
Analysts have trimmed their average price target on Azenta from about $43.50 to roughly $38.67, reflecting recent target cuts of $5 and $9, along with updated views on revenue growth, margins and a lower future P/E assumption. Analyst Commentary Recent research shows a mixed but detailed set of views around Azenta, with some focusing on long term growth potential and others dialing back expectations on valuation and near term execution.
Nuova narrazione • Feb 08
Multiomics Outsourcing And Automation Will Drive A Powerful Long Term Earnings Shift
Catalysts About Azenta Azenta provides life sciences customers with sample management, multiomics services and automation solutions across biorepositories, sequencing and gene synthesis. What are the underlying business or industry changes driving this perspective?Aggiornamento della narrazione • Feb 03
AZTA: 2026 Margin Path And Buybacks Will Support Upside Potential
Analysts have nudged up their Azenta targets, with one moving to US$39 and another to US$45. This reflects interest in the company’s multi year growth framework and expectations for mid single digit organic revenue trends, with a path to margins above 20%.Aggiornamento della narrazione • Jan 20
AZTA: Biopharma Exposure And 2026 Margin Path Support Balanced Risk Reward
Analysts have lifted their price target on Azenta to about US$43.50 from roughly US$40.17, citing slightly lower revenue growth expectations, firmer profit margin assumptions and a modestly lower future P/E outlook. The revised target is supported by recent research that notes improving sentiment, mid single digit organic revenue ambitions and a path to higher margins into 2026.Aggiornamento della narrazione • Jan 05
AZTA: Biopharma Exposure Will Support Margin Expansion And 2026 Re Rating Potential
Analysts have nudged their fair value estimate for Azenta slightly higher to about $40, reflecting updated price targets in the mid to high $30s and low $40s, and their view that organic revenue growth and margin expansion potential into 2026 support a more constructive outlook on the shares. Analyst Commentary Recent research updates highlight a more constructive tone on Azenta, with several firms lifting price targets and turning more positive after the latest fiscal Q4 report and ahead of the upcoming investor day.Aggiornamento della narrazione • Dec 14
AZTA: Biopharma Exposure Will Support Mid-Single-Digit Growth And Margin Expansion
Azenta's analyst price target has been raised by $10 to $45, as analysts point to mid single digit plus organic revenue growth prospects and a credible path to margins above 20% that is supported by healthy biopharma exposure and multiple growth drivers into 2026. Analyst Commentary Bullish analysts highlight that the latest results, while largely in line with expectations, reinforce confidence in Azenta's ability to sustain mid single digit plus organic revenue growth while steadily expanding margins above 20% over the medium term.Aggiornamento della narrazione • Nov 29
AZTA: Mid-Single-Digit Organic Revenue Acceleration Will Broaden Profit Margins Into 2026
Azenta's analyst price target has increased from $35.17 to $39.83. Analysts cite in-line financial results and ongoing optimism around revenue growth and expanding profit margins, supported by sector exposure and long-term innovation opportunities.Articolo di analisi • Nov 28
Azenta's (NASDAQ:AZTA) Earnings Offer More Than Meets The Eye
Investors signalled that they were pleased with Azenta, Inc.'s ( NASDAQ:AZTA ) most recent earnings report. Looking...Aggiornamento della narrazione • Nov 14
AZTA: Growth Drivers From Biopharma Exposure And Acquisitions Will Unlock Opportunity
Analysts have raised their price target for Azenta from $30 to $38, citing expectations for increased growth opportunities and a positive outlook. This outlook is based on innovation, robust biopharma exposure, and prospective acquisitions.Aggiornamento della narrazione • Oct 30
AZTA: Biopharma Demand and Acquisition Focus Will Drive Shares Higher Through 2026
Azenta's analyst price target has been raised from $33 to approximately $35.17 per share. Analysts cite increased confidence in the company's growth drivers and mid-term opportunities, particularly within the biopharma sector.Articolo di analisi • Sep 12
Is There Now An Opportunity In Azenta, Inc. (NASDAQ:AZTA)?
While Azenta, Inc. ( NASDAQ:AZTA ) might not have the largest market cap around , it saw a decent share price growth of...Articolo di analisi • Aug 07
Azenta, Inc. (NASDAQ:AZTA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
NasdaqGS:AZTA 1 Year Share Price vs Fair Value Explore Azenta's Fair Values from the Community and select yours It's...Articolo di analisi • Jul 24
Calculating The Fair Value Of Azenta, Inc. (NASDAQ:AZTA)
Key Insights Azenta's estimated fair value is US$38.26 based on 2 Stage Free Cash Flow to Equity Current share price of...Nuova narrazione • May 28
Pharma And Biotech Outsourcing Will Shape Future Market Dynamics
Strong industry trends and Azenta's infrastructure investments are driving above-market growth, recurring revenues, and operating leverage in sample management and biobanking.Seeking Alpha • Apr 17
Azenta: Life Science Business Failing To Come To Life
Summary Azenta, formerly Brooks Automation, has struggled to show organic growth and profitability, leading to a significant drop in its stock price. Despite a strong balance sheet and reduced valuation, the company needs to deliver real margin growth and profitability to attract investors. The company has faced challenges, including a decline in organic sales and the departure of its CEO, but continues to make strategic moves like selling B Medical Systems. Given the compressed sales multiples and strong cash position, a speculative position might be warranted, but management must prove its ability to improve earnings. Read the full article on Seeking AlphaArticolo di analisi • Apr 05
Azenta, Inc.'s (NASDAQ:AZTA) 29% Share Price Plunge Could Signal Some Risk
Unfortunately for some shareholders, the Azenta, Inc. ( NASDAQ:AZTA ) share price has dived 29% in the last thirty...Articolo di analisi • Mar 28
Are Investors Undervaluing Azenta, Inc. (NASDAQ:AZTA) By 50%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Azenta fair value estimate is US$70.94 Current share price of...Seeking Alpha • Jan 27
Azenta: Taking A Pass
Summary Azenta, Inc. shares have surged over 30% since Nov 2024 due to S&P 600 inclusion and an analyst upgrade, despite somewhat tepid growth prospects. The company is restructuring to save $30-$40 million by FY26, divesting a business segment, and has a strong balance sheet. An analysis on Azenta, Inc. follows in the paragraphs below. Read the full article on Seeking AlphaArticolo di analisi • Jan 10
At US$51.81, Is Azenta, Inc. (NASDAQ:AZTA) Worth Looking At Closely?
Azenta, Inc. ( NASDAQ:AZTA ), is not the largest company out there, but it received a lot of attention from a...Articolo di analisi • Dec 20
A Look At The Intrinsic Value Of Azenta, Inc. (NASDAQ:AZTA)
Key Insights The projected fair value for Azenta is US$56.65 based on 2 Stage Free Cash Flow to Equity With US$49.50...Articolo di analisi • Nov 17
Analysts Have Just Cut Their Azenta, Inc. (NASDAQ:AZTA) Revenue Estimates By 14%
The analysts covering Azenta, Inc. ( NASDAQ:AZTA ) delivered a dose of negativity to shareholders today, by making a...Articolo di analisi • Nov 14
Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price
It's not a stretch to say that Azenta, Inc.'s ( NASDAQ:AZTA ) price-to-sales (or "P/S") ratio of 3.1x right now seems...Seeking Alpha • Sep 11
Azenta: Life Science Play Is Not Coming To Life
Summary Azenta, Inc., formerly Brooks Automation, has struggled after the sale of its semiconductor business, as the remaining life sciences business has failed to turn a profit. Following aggressive share buybacks, Azenta's valuation remains demanding, with high earnings multiples and significant discrepancies between GAAP and non-GAAP earnings. New CEO John Marotta brings industry experience, but immediate results are unlikely, as the company needs to improve its margin profile and organic growth. I remain cautious on Azenta, monitoring its progress under new leadership, despite the seemingly low sales multiple and strong revenue base. Read the full article on Seeking AlphaArticolo di analisi • Jul 19
Azenta, Inc.'s (NASDAQ:AZTA) Shares May Have Run Too Fast Too Soon
When close to half the companies in the Life Sciences industry in the United States have price-to-sales ratios (or...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$111m |
| Dec 31 2025 | n/a | n/a | US$26m |
| Sep 30 2025 | US$10m | US$900k | US$24m |
| Jun 30 2025 | n/a | n/a | -US$27m |
| Mar 31 2025 | n/a | n/a | -US$28m |
| Dec 31 2024 | n/a | n/a | -US$24m |
| Sep 30 2024 | US$1m | US$35k | -US$24m |
Compensazione vs Mercato: La retribuzione totale di John P. ($USD 10.37M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 3.79M ).
Compensazione vs guadagni: La retribuzione di John P. è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
John P. Marotta (44 yo)
1.7yrs
Mandato
US$10,371,415
Compensazione
Mr. John P. Marotta is President, CEO & Director of Azenta, Inc. from September 9, 2024. He joined the Azenta, Inc. on September 9, 2024. He is Chief Executive of EMERGE Medical Inc. He is Member of Adviso...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 1.7yrs | US$10.37m | 0.083% $ 671.9k | |
| Executive VP & CFO | 1.5yrs | US$3.91m | 0.054% $ 436.5k | |
| Senior VP | 1yr | US$2.80m | 0.15% $ 1.2m | |
| Senior VP & Chief HR Officer | 2.8yrs | US$1.70m | 0.012% $ 97.5k | |
| Advisor | 7yrs | US$1.55m | 0.027% $ 221.5k | |
| VP, Chief Information & Digital Officer | 8.8yrs | Nessun dato | Nessun dato | |
| Vice President of Financial Planning & Analysis and Investor Relations | no data | Nessun dato | Nessun dato | |
| Senior Vice President & President of Multiomics | less than a year | Nessun dato | Nessun dato | |
| Strategic Technical Specialist of Azenta Life Sciences | no data | Nessun dato | Nessun dato | |
| Vice President and General Manager of Sample Repository Solutions | no data | Nessun dato | Nessun dato |
1.7yrs
Durata media
49yo
Età media
Gestione esperta: Il team dirigenziale di AZTA non è considerato esperto (durata media 1.7 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 1.7yrs | US$10.37m | 0.083% $ 671.9k | |
| Independent Director | 3.3yrs | US$293.25k | 0.034% $ 278.4k | |
| Independent Director | 2.3yrs | US$295.12k | Nessun dato | |
| Independent Vice Chair of the Board | 12.9yrs | US$303.19k | 0.088% $ 717.2k | |
| Independent Director | 1.5yrs | US$288.87k | 0.059% $ 477.4k | |
| Independent Director | 6.1yrs | US$301.37k | 0.049% $ 397.5k | |
| Independent Director | 1.3yrs | US$267.62k | 0.021% $ 171.2k | |
| Independent Chairman | 4.5yrs | US$404.77k | 0.047% $ 384.8k | |
| Independent Director | 1.5yrs | US$289.50k | 0.011% $ 88.8k |
2.3yrs
Durata media
61yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di AZTA non è considerato esperto (durata media del mandato 2.3 anni), il che suggerisce un nuovo consiglio.
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/20 14:05 |
| Prezzo dell'azione a fine giornata | 2026/05/20 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/09/30 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Azenta, Inc. è coperta da 15 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Christopher Muse | Barclays |
| Brett Hodess | BofA Global Research |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |